McArdle's disease and anaesthesia: Case reports. Review of potential problems and association with malignant hyperthermia

Acta Anaesthesiologica Scandinavica

Volumn 49, Issue 8, 2005, Pages 1077-1083

  Bollig, Georg ^a,b   Mohr, S ^a   Raeder J ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b TELEMARK HOSPITAL   (Norway)

Author keywords

Anaesthesia; Complications; Glycogen storage disease type V; Halothane; Malignant hyperthermia; McArdle's disease; Succinylcholine

Indexed keywords

CONTRACTURE; GENERAL ANESTHESIA; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; HYPOTENSION; IN VITRO STUDY; LOCAL ANESTHESIA; LUNG EDEMA; MALIGNANT HYPERTHERMIA; MEDICAL RECORD; PERIOPERATIVE PERIOD; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; RHABDOMYOLYSIS; TACHYCARDIA;

EID: 23944466722     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2005.00755.x     Document Type: Review

References (32)

1. DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 1994: 1554-76.
2. Bartram C, Edwards RHT, Beynon RJ. McArdle's disease-muscle glycogen phosphorylase deficiency. Biochim Biophys Acta 1995; 1272: 1-13.
3. Kubisch C, Wicklein EM, Jentsch TJ. Molecular diagnosis of McArdle disease: revised genomic structure of the myophosphorylase gene and identification of a novel mutation. Hum Mutat 1998; 12: 27-32.
4. Bollig G. Das McArdle-Syndrom (Glykogenose Typ 5) unter sportmedizinischen Gesichtspunkten. Köln: Inaugural Dissertation Universität zu Köln, 2000.
5. Vissing J, Haller RG. A diagnostic cycle test for McArdle's disease. Ann Neurol 2003; 54: 539-42.
6. Ito Y, Saito K, Shishikura K et al. A 1-year-old infant with McArdle disease associated with hyper-creatine kinase-emia during febrile episodes. Brain Dev 2003; 25: 438-41.
7. Bruno C, Bertini E, Santorelli FM, DiMauro S. HyperCKemia as the only sign of McArdle's disease in a child. J Child Neurol 2000; 15: 137-8.
8. Wappler F, Fiege M, Steinfath M et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94: 95-100.
9. Quinlivan R, Beynon RJ, Quinlivan R, Beynon RJ. Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V). Cochrane Database Syst Rev 2004; 3: CD003458.
10. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003; 349: 2503-9.
11. Pernow BB, Havel RJ, Jenning DB. The second wind phenomenon in McArdle's disease. Acta Med Scand 1967; 472: 294-307.
12. Bundschuh HD, Pfeiffer J, Schlote W. Akutes Nierenversagen bei McArdle-Syndrom. Verh Dtsch Ges Inn Med 1977; 83: 1280-93.
13. Stamos GE, Crouch TT, Wood WG, Sharma JN. Acute renal failure in McArdle's disease. South Med J 1979; 72: 77-9.
14. McMillan MA, Hallworth Mj Doyle D, Briggs JD, Junor BJR. Acute renal failure due to McArdle's disease. Ren Fail 1989; 11: 23-5.
15. Tsushima K, Koyama S, Ueno M et al. Rhabdomyolysis triggered by an asthmatic attack in a patient with McArdle disease. Intern Med 2001; 40: 131-4.
16. Meinck HM, Goebel HH, Rumpf KW, Kaiser H, Neumann P. The forearm ischaemic work test-hazardous to McArdle patients? J Neurol Neurosurg Psychiatry; 1 (982): 45: 1144-6.
17. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18: 632-52.
18. Ørding H. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955-66.
19. Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997; 84: 1038-41.
20. Isaacs H, Badenhorst ME, Du Sautoy C. Myophosphorylase B deficiency and malignant hyperthermia. Muscle Nerve 1989; 12: 203-5.
21. Lobato EB, Janelle GM, Urdaneta F, Malias MA. Noncardiogenic pulmonary edema and rhabdomyolysis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 1999; 91: 303-5.
22. Lane RJM, Turnbull DM, Hudgson P, Walton J. Trials of verapamil and dantrolene sodium in McArdle disease. Muscle Nerve 1984; 9: 592-3.
23. Heytens L, Martin JJ, Van de Kelft E, Bossaert LL. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth 1992; 68: 72-5.
24. Carr AS, Lermann J, Cunliffe M, McLeod ME, Britt BA. Incidence of malignant hyperthermia reactions in 2214 patients undergoing muscle biopsy. Can J Anaesth 1995; 42: 281-6.
25. Ørding H, Hedengran AM, Skovgaard LT. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol Scand 1991; 35: 711-6.
26. Rajah A, Bell CF. Atracurium and McArdle's disease. Anaesthesia 1986; 41: 93.
27. Tzabar Y, Ross DG. Vecuronium and McArdle's disease. Anaesthesia 1990; 45: 697.
28. Lepoivre T, Legendre E, Pinaud M. Anaesthesia for cesarean section in a patient with McArdle disease and hereditary dilated cardiomyopathy. Ann Fr Anesth Reanim 2002; 21: 517-20.
29. Coleman P. McArdle's disease. Problems of anaesthetic management for Caesarean section. Anaesthesia 1984; 39: 784-7.
30. Samuels TA, Coleman P. McArdle's disease and cesarean section. Anaesthesia 1988; 43: 161-2.
31. Brown BR, Walson PD, Taussig LM. Congenital metabolic diseases of pediatric patients: anesthetic implications. Anesthesiology 1975; 45: 197-209.
32. Ellis FR. Inherited muscle disease. Br J Anaesth 1980; 52: 153-64.